Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
99279 trials found · Page 2 of 4964
-
Breakthrough 'Ultra-Transplant' could cure thalassemia without chemo or rejection risk
⭐️ CURE ⭐️ Recruiting nowYunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of…
Phase: NA • Sponsor: Hu Peng • Aim: ⭐️ CURE ⭐️
Last updated May 27, 2026 12:02 UTC
-
Gene editing breakthrough: CRISPR therapy targets sickle cell pain
Disease control Recruiting nowThis is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SC…
Phase: PHASE1, PHASE2 • Sponsor: Mark Walters, MD • Aim: Disease control
Last updated May 30, 2026 09:20 UTC
-
Monthly pill could replace daily HIV prevention
Prevention Recruiting nowResearchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophyla…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated May 26, 2026 12:04 UTC
-
One-shot gene therapy aims to stop bleeding in teens with hemophilia b
Disease control Recruiting nowThis is a phase 3, prospective, open-label, single-arm, single-dose, multicenter study investigating the efficacy, safety, and tolerability of CSL222 (AAV5-hFIXco-Padua) in adolescent male participants with severe or moderately severe hemophilia B.
Phase: PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated May 30, 2026 09:19 UTC
-
Yearly HIV prevention shot could replace daily pills
Prevention Recruiting nowThe goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophy…
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Prevention
Last updated May 27, 2026 23:06 UTC
-
Breakthrough pill could stop rare genetic disease before it starts
Prevention Recruiting nowTransthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR…
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated May 29, 2026 14:16 UTC
-
Bubble boy disease: gene editing trial offers new hope
Disease control ENROLLING_BY_INVITATIONBackground: X-linked severe combined immunodeficiency (XSCID) is a rare inherited disorder that affects the immune system. It is caused by a change in the IL2RG gene. Researchers are investigating a new type of gene therapy for people with XSCID. This technique, called base-edit…
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated May 29, 2026 14:19 UTC
-
New trial aims to Fine-Tune wilms tumor treatment, boosting cure rates for kids
⭐️ CURE ⭐️ Recruiting nowThis phase III trial studies using risk factors in determining treatment for children with favorable tissue (histology) Wilms tumors (FHWT). Wilms Tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have …
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: ⭐️ CURE ⭐️
Last updated May 30, 2026 09:18 UTC
-
Promising new combo may extend life in aggressive brain cancer
Disease control Recruiting nowBackground: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significant…
Phase: PHASE3 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Could this drug stop Alzheimer's before it starts? new trial aims to find out
Prevention Recruiting nowThe purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of r…
Phase: PHASE2, PHASE3 • Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated May 30, 2026 09:18 UTC
-
Groundbreaking trial aims to prevent Alzheimer's in those genetically destined to get it.
Prevention Recruiting nowThe purpose is to evaluate the biomarker effect, safety, and tolerability of investigational study drugs in participants who are known to have an Alzheimer's disease (AD)-causing mutation. Stage 1 will determine if treatment with the study drug prevents or slows the rate of amylo…
Phase: PHASE2, PHASE3 • Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated May 27, 2026 11:51 UTC
-
Could this powder cure food allergies in babies?
⭐️ CURE ⭐️ Recruiting nowThe aim is to study whether a multiallergen oral immunotherapy (OIT) strategy with slow up-dosing and low treatment dose against food allergy in young children (0.5-3 years) is safe and effective, a method to cure food allergy and to prevent the development of new food allergies.…
Phase: NA • Sponsor: Karolinska Institutet • Aim: ⭐️ CURE ⭐️
Last updated May 29, 2026 14:16 UTC
-
One-shot gene fix aims to rebuild immune system in babies with bubble boy disease
Disease control Recruiting nowThis is a Phase I/II trial of in vivo lentiviral gene therapy for treating adenosine deaminase severe combined immunodeficiency (ADA-SCID) using a self-inactivating lentiviral vector (LV) ivlv-ADA to functionally correct the genetic defect. The primary objectives are to evaluate …
Phase: NA • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated May 26, 2026 11:59 UTC
-
New combo aims to cure hepatitis b in over half of patients
⭐️ CURE ⭐️ Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Phase: PHASE4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: ⭐️ CURE ⭐️
Last updated May 26, 2026 12:12 UTC
-
One-Time gene fix could free babies from lifelong liver drugs
Disease control Recruiting nowOrnithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxifying of ammonia. Individuals with OTC deficiency can develop elevated levels of ammonia in the …
Phase: PHASE1, PHASE2 • Sponsor: iECURE, Inc. • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
Massive TB vaccine trial aims to stop a global killer
⭐️ VACCINE ⭐️ OngoingThe study is a randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mtb vaccine when administered intramuscularly (IM) on a 0,1-month schedule to adolescents an…
Phase: PHASE3 • Sponsor: Gates Medical Research Institute • Aim: ⭐️ VACCINE ⭐️
Last updated May 29, 2026 14:18 UTC
-
Gene therapy offers hope for kids with rare NGLY1 disorder
Disease control OngoingA non-randomized, open-label, Phase 1/2/3 study of a single intracerebroventricular (ICV) administration of a gene replacement therapy (GS-100) in participants who are 2 to 18 years old with NGLY1 Deficiency.
Phase: PHASE3 • Sponsor: Grace Science, LLC • Aim: Disease control
Last updated May 26, 2026 12:04 UTC
-
Mind-Controlled tech: neuralink implants brain chip in paralysis patients
Disease control Recruiting nowThe PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or tetraplegia. The N1 Implant is a skull-mounted, wireless, rech…
Phase: NA • Sponsor: Neuralink Corp • Aim: Disease control
Last updated May 30, 2026 09:21 UTC
-
Gene therapy shows promise in battle against rare childhood disease
Disease control OngoingA multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
Phase: PHASE3 • Sponsor: Orchard Therapeutics • Aim: Disease control
Last updated May 29, 2026 14:20 UTC
-
New drug could cure rare immune disorder with safer transplants
⭐️ CURE ⭐️ OngoingBackground: People with GATA2 deficiency have a mutation on the GATA2 gene. This gene affects immune function. People with this disease are prone to serious infections; in time, they may develop blood cancers. A hematopoietic stem cell (HSC) transplant can cure GATA2 deficiency,…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated May 29, 2026 14:19 UTC